Antiphospholipid antibody testing for the antiphospholipid syndrome: A comprehensive practical review including a synopsis of challenges and recent guidelines

Pathology

Volumn 46, Issue 6, 2014, Pages 481-495

  Favaloro, Emmanuel J ^a   Wong, Richard C W ^b  

^a WESTMEAD HOSPITAL   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Anti beta 2 Glycoprotein I antibodies; Anticardiolipin antibodies; Antiphospholipid antibodies; Antiphospholipid syndrome; APL; APS; Diagnosis; Guidelines; Laboratory testing; Lupus anticoagulant

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; IMMUNOLOGIC FACTOR; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ALGORITHM; ANTIPHOSPHOLIPID SYNDROME; CLASSIFICATION; FEMALE; HUMAN; IMMUNOLOGY; LABORATORY TECHNIQUE; PRACTICE GUIDELINE; PREGNANCY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; THROMBOSIS;

ALGORITHMS; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CLINICAL LABORATORY TECHNIQUES; FEMALE; GUIDELINES AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; LUPUS COAGULATION INHIBITOR; PREGNANCY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THROMBOSIS;

EID: 84961290266     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000142     Document Type: Article

References (82)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Hughes GR. Hughes syndrome. The antiphospholipid syndrome - a clinical overview. Clin Rev Allergy Immunol 2007; 32: 3-11.
3. Favaloro EJ, Wong RCW. The antiphospholipid syndrome: A large elephant with many parts or an elusive chameleon disguised by many colours? Autoimmunity Highlights 2010; 1: 5-14.
4. Gillis D, Wong RC. Rarer clinical associations of antiphospholipid antibodies. Semin Thromb Hemost 2012; 38: 328-32.
5. Gris JC, Brenner B. Antiphospholipid antibodies: neuropsychiatric presentations. Semin Thromb Hemost 2013; 39: 935-42.
6. Harris EN, Pierangeli SS. Primary, secondary and catastrophic antiphospholipid syndrome: What's in a name? Semin Thromb Hemost 2008; 34: 219-26.
7. Asherson RA. The primary, secondary, catastrophic and seronegative variants of the antiphospholipid syndrome: A personal history long in the making. Semin Thromb Hemost 2008; 34: 227-35.
8. Les I, Ruiz-Irastorza G, Khamashta MA. Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. Semin Thromb Hemost 2012; 38: 339-47.
9. Siesdedos L, Munoz-Rodriguez FJ, Cervera R, et al. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. Lupus 1997; 6: 285-6.
10. Dhillon PK, Adams MJ. Thrombosis in systemic lupus erythematosus: role of impaired fibrinolysis. Semin Thromb Hemost 2013; 39: 434-40.
11. Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the 'CAPS Registry'. Semin Thromb Hemost 2012; 38: 333-8.
12. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
13. Favaloro EJ, Wong RC. Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions. Semin Thromb Hemost 2008; 34: 389-410.
14. Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000; 43: 440-3.
15. Wong RCW, Favaloro EJ. A consensus approach to the formulation of guidelines for laboratory testing and reporting of antiphospholipid antibody assays. Semin Thromb Hemost 2008; 34: 361-72.
16. Willis R, Harris EN, Pierangeli SS. Pathogenesis of the antiphospholipid syndrome. Semin Thromb Hemost 2012; 38: 305-21.
17. Van Hoecke F, Persijn L, Decavele AS, Devreese K. Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Int J Lab Hematol 2012; 34: 630-40.
18. Favaloro EJ, Plebani M, Lippi G. Regulation in hemostasis and thrombosis: Part I - in vitro diagnostics. Semin Thromb Hemost 2013; 39: 235-49.
19. Passam F, Krilis S. Laboratory tests for the antiphospholipid syndrome: current concepts. Pathology 2004; 36: 129-38.
20. Oku K, Atsumi T, Amengual O, Koike T. Antiprothrombin antibody testing: detection and clinical utility. Semin Thromb Hemost 2008; 34: 335-9.
21. Galli M, Luciani D, Bertolini G, et al. Antiprothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-23.
22. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors of thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-32.
23. Galli M. Interpretation and recommended testing for antiphospholipid antibodies. Semin Thromb Hemost 2012; 38: 348-52.
24. Pengo V, Banzato A, Bison E, et al. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? Semin Thromb Hemost 2012; 38: 322-7.
25. Roubey RA. Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice. Lupus 2010; 19: 440-5.
26. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7: 1737-40.
27. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. British Committee for Standards in Haematology Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157: 47-58.
28. Clinical and Laboratory Standards Institute (CLSI). Laboratory Testing for the Lupus Anticoagulant; Approved Guideline. CLSI document H60-A. Wayne, PA: CLSI, 2014.
29. McGlasson DL, Fritsma GA. Comparison of six dilute Russell viper venom time lupus anticoagulant screen/confirm assay kits. Semin Thromb Hemost 2013; 39: 315-9.
30. Pradella P, Azzarini G, Santarossa L, et al. Cooperation experience in a multicenter study to define the upper limits in a normal population for the diagnostic assessment of the functional lupus anticoagulant assays. Clin Chem Lab Med 2013; 2: 379-85.
31. Favaloro EJ. Trials and tribulations in lupus anticoagulant testing. Clin Chem Lab Med 2013; 51: 253-6.
32. Favaloro EJ. Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants. Int J Lab Hematol 2013; 35: 269-74.
33. Pierangeli SS, Favaloro EJ, Lakos G, et al. Standards and reference materials for the anticardiolipin and anti-β(2)glycoprotein I assays: A report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. Clin Chim Acta 2012; 413: 358-60.
34. th International Congress on Antiphospholipid Antibodies. Arthritis Rheum 2012; 64: 1-10.
35. Pierangeli S, Groot P, Dlott J, et al. 'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. Lupus 2011; 20: 182-90.
36. de Groot PG, Urbanus RT. The future of antiphospholipid antibody testing. Semin Thromb Hemost 2012; 38: 412-20.
37. Forastiero R, Papalardo E, Watkins M, et al. Evaluation of the performance of monoclonal and polyclonal antibody standards in different assays for the detection of antiphospholipid antibodies: report of a wet workshop at the 13th International Congress on Antiphospholipid (aPL) Antibodies. Arthritis Rheum 2010; 62 (Suppl): S946.
38. Favaloro EJ, Wheatland L, Jovanovich S, et al. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I - anti-cardiolipin and anti-β2-glycoprotein I antibodies. Semin Thromb Hemost 2012; 38: 390-403.
39. Favaloro EJ, Bonar R, Marsden K. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part II - lupus anticoagulant. Semin Thromb Hemost 2012; 38: 404-11.
40. Wong RCW, Favaloro EJ, Pollock W, et al. A multi-centre evaluation of the intra-assay and inter-assay variation of commercial and in-house anticardiolipin antibody assays. Pathology 2004; 36: 182-92.
41. Favaloro EJ, Wong R. Laboratory testing for the Antiphospholipid Syndrome: making sense of antiphospholipid antibody assays. Clin Chem Lab Med 2011; 49: 447-61.
42. Wong RCW, Gillis D, Adelstein S, et al. Consensus guidelines on anti-cardiolipin antibody testing and reporting. Pathology 2004; 361: 63-8.
43. Wong RC, Favaloro EJ, Adelstein S, et al. Consensus guidelines on antibeta2 glycoprotein I testing and reporting. Pathology 2008; 40: 58-63.
44. Devreese KM, Pierangeli SS, de Laat B, et al. Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 2014; 12: 792-5.
45. Willis R, Harris EN, Pierangeli SS. Current international initiatives in antiphospholipid antibody testing. Semin Thromb Hemost 2012; 38: 360-74.
46. Willis R, Lakos G, Harris EN. Standardization of antiphospholipid antibody testing - historical perspectives and ongoing initiatives. Semin Thromb Hemost 2014; 40: 172-7.
47. th ed. CLSI document H21-A5. Wayne, PA: CLSI, 2007.
48. Favaloro EJ, Funk (Adcock) DM, Lippi G. Pre-analytical variables in coagulation testing associated with diagnostic errors in hemostasis. Lab Medicine 2012; 43: 1-10.
49. Froom P, Barak M. Testing for lupus anticoagulants-fresh or frozen? Clin Chem Lab Med 2012; 50: 1607-9.
50. Adcock Funk DM, Lippi G, Favaloro EJ. Quality standards for sample processing, transportation, and storage in hemostasis testing. Semin Thromb Hemost 2012; 38: 576-85.
51. Lippi G, Salvagno GL, Montagnana M, et al. Quality standards for sample collection in coagulation testing. Semin Thromb Hemost 2012; 38: 565-75.
52. Wong RC, Favaloro EJ. The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti-β2-glycoprotein-1 ELISAs: a rebuttal. J Thromb Haemost 2006; 4: 1434-5.
53. Tripodi A. Problems and solutions for testing hemostasis assays while patients are on anticoagulants. Semin Thromb Hemost 2012; 38: 586-92.
54. Tripodi A. To mix or not to mix in lupus anticoagulant testing? That is the question. Semin Thromb Hemost 2012; 38: 385-9.
55. Favaloro EJ, Reben R, Mohammed S, Koutts J. A clinical audit of antiphospholipid antibody testing in tertiary practice. Towards improved relevance in thrombophilia investigations? Internal Med J 2012; 42: 427-34.
56. Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants - the present and the future. Pathology 2011; 43: 682-92.
57. Favaloro EJ, Lippi G. The new oral anticoagulants and the future of haemostasis laboratory testing. Biochem Med 2012; 22: 329-41.
58. Kershaw G, Suresh S, Orellana D, Nguy YM. Laboratory identification of lupus anticoagulants. Semin Thromb Hemost 2012; 38: 375-84.
59. Galli M, Borrelli G, Jacobsen EM, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007; 110: 1178-83.
60. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3: 1231-8.
61. Brusch A, Bundell C, Hollingsworth P. Immunoglobulin G is the only antibeta- 2-glycoprotein I isotype that associates with unprovoked thrombotic events among hospital patients. Pathology 2014; 6: 234-9.
62. Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 2014; 123: 404-13.
63. Gris JC, Bouvier S, Molinari N, et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood 2012; 119: 2624-32.
64. Galli M. The antiphospholipid triangle. J Thromb Haemost 2010; 8: 234-6.
65. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237-42.
66. Favaloro EJ, Wong RC. Current clinical and laboratory practice for the investigation of the antiphospholipid syndrome: findings from the 2008 Australasian antiphospholipid antibody survey. Pathology 2009; 41: 666-75.
67. Bertolaccini ML, Amengual O, Atsumi T, et al. 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus 2011; 20: 191-205.
68. Murthy V, Willis R, Romay-Penabad Z, et al. Value of isolated IgA anti-β2 - glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 2013; 65: 3186-93.
69. Lakos G. Interference in antiphospholipid antibody assays. Semin Thromb Hemost 2012; 38: 353-9.
70. Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 2014; 40: 163-71.
71. Manoussakis MN, Tzioufas AG, Silis MP, et al. High prevalence of anticardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol 1987; 69: 557-65.
72. El-Roeiy A, Gleicher N. Definition of normal autoantibody levels in an apparently healthy population. Obstet Gynecol 1988; 72: 596-602.
73. Shi W, Krilis SA, Chong BH, et al. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med 1990; 20: 231-6.
74. Kershaw G, Orellana D. Mixing tests: diagnostic aides in the investigation of prolonged prothrombin times and activated partial thromboplastin times. Semin Thromb Hemost 2013; 39: 283-90.
75. Favaloro EJ, Bonar R, Zebeljan D, et al. Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. J Thromb Haemost 2010; 8: 2828-31.
76. Bonar R, Favaloro EJ, Zebeljan D, et al. Evaluating laboratory approaches to the identification of lupus anticoagulants: A diagnostic challenge from the RCPA Haematology QAP. Pathology 2012; 44: 240-7.
77. Tripodi A, Pengo V. More on: laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. J Thromb Haemost 2011; 9: 2126-7.
78. Favaloro EJ, Bonar R, Marsden K. Lupus anticoagulant testing - sometimes mixing is required: potential for false negatives without mixing studies. Blood Coagul Fibrinolysis 2013; 24: 673-6.
79. Bonar R, Favaloro EJ, Adcock D. Quality in coagulation and haemostasis testing. Biochem Med 2010; 20: 184-99.
80. Wong RCW, Wilson RJ, Pollock W, et al. Anti-cardiolipin antibody testing and reporting practices among laboratories participating in a large external Quality Assurance Program. Pathology 2004; 36: 174-81.
81. Favaloro EJ, Lippi G. Laboratory reporting of haemostasis assays: The final post-analytical opportunity to reduce errors of clinical diagnosis in hemostasis? Clin Chem Lab Med 2010; 48: 309-21.
82. Adams M. Measurement of lupus anticoagulants: an update on quality in laboratory testing. Semin Thromb Hemost 2013; 39: 267-71.